Watch for regulatory clearance milestones (HSR and state health care approvals) as the key gating items to close by early 2027. Myriad's Q3 earnings call on November 4, 2026, will provide further commentary on the transaction and organizational changes.
Price Chart
Executive Summary
Myriad Genetics (MYGN) has entered into a definitive asset purchase agreement to sell its Prenatal Health testing business (Prequel, Foresight, SneakPeek, and FirstGene tests) to Labcorp (LH) for $210 million in cash, plus the value of inventory at closing. The transaction is expected to close by early 2027, subject to regulatory clearance and customary conditions. Myriad expects the sale to be accretive to revenue growth and profitability while strengthening its balance sheet to focus on its cancer care portfolio.
Key Financial Metrics
Key Facts
- Myriad Genetics sells its Prenatal Health testing business to Labcorp for $210 million in cash, plus inventory value at closing.
- Labcorp expects the transaction to add approximately $160 million in revenue in year one and be slightly accretive to adjusted earnings.
- The deal is expected to close by early 2027, subject to HSR clearance, state health care law approvals, and other customary conditions.
- Myriad expects the transaction to be accretive to its revenue growth and profitability, and to strengthen its balance sheet for investment in its cancer care strategic priorities.
- A reverse termination fee of $10.5 million is payable by Labcorp under certain regulatory failure scenarios.
- The Prenatal Health portfolio served over 600,000 patients in the last twelve months.
Financial Impact
Myriad receives $210 million cash plus inventory value; Labcorp expects ~$160M year-one revenue from the acquired business.
Risk Factors
- Regulatory clearance failure could delay or block the transaction; Labcorp would owe a $10.5M reverse termination fee.
- Integration risk for Labcorp in achieving targeted margins by end of year two.
- Potential disruption to Myriad's remaining business during the transition period.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000899923-26-000094 |
| Exhibit: ex991pressreleaseofmyriadg.htm | 0000899923-26-000094 |
| Document: mygn-20261019.htm | 0000899923-26-000094 |
| Document: 0000899923-26-000094-index-headers.html | 0000899923-26-000094 |
| Document: 0000899923-26-000094-index.html | 0000899923-26-000094 |
| Document: 0000899923-26-000094.txt | 0000899923-26-000094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $6.02 | awaiting T+1 | awaiting T+1 | $6.29 (+4.49%) |
Oct 20, 2026 7d ago | 8-K | $5.54 $5.57 | ▲ +0.54% | ▲ +0.02% | $6.29 (+13.54%) |
Oct 15, 2026 12d ago | Press Release | $3.98 | awaiting T+1 | awaiting T+1 | $6.29 (+58.04%) |
Oct 9, 2026 18d ago | 8-K | $4.20 $4.08 | ▼ −2.86% | ▼ −2.85% | $6.29 (+49.76%) |
Sep 16, 2026 5w ago | 8-K | $3.86 $4.14 | ▲ +7.25% | ▲ +6.12% | $6.29 (+62.95%) |
Sep 16, 2026 5w ago | Press Release | $3.86 $4.14 | ▲ +7.25% | ▲ +6.12% | $6.29 (+62.95%) |
Jul 30, 2026 12w ago | Press Release | $2.86 $3.02 | ▼ −5.59% | ▼ −4.17% | $6.29 (−119.93%) |
May 27, 2026 21w ago | Press Release | $3.93 $4.22 | ▲ +7.38% | ▲ +6.83% | $6.29 (+60.05%) |
Mar 17, 2026 32w ago | Press Release | $4.64 $4.75 | ▲ +2.37% | ▲ +2.64% | $6.29 (+35.56%) |
Feb 28, 2026 34w ago | Institutional Cluster | $5.01 $5.29 | ▲ +5.59% | ▲ +6.50% | $6.29 (+25.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers